ArticleDiscover oncology2025
Identifying candidate biomarkers for detecting bronchogenic carcinoma stages using metaheuristic algorithms based on information fusion theory.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discovery of drug candidate to inhibit bronchogenic carcinoma genes biomarkers based on drug repurposing.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveInvasive lung cancer staging poses significant challenges, often requiring painful and costly biopsy procedures. This study aims to identify non-invasive biomarkers for detecting bronchogenic carcinoma and its various stages by analyzing gene expression data using bioinformatics and machine learning techniques. By leveraging these advanced computational methods, we seek to eliminate the need for surgical intervention in the diagnostic process.
methodsWe utilized the TCGA-LUAD dataset, including gene expression data from healthy and cancerous samples. To identify robust biomarkers, we applied eight metaheuristic algorithms for feature selection, combined with four classification methods and two data fusion techniques to optimize performance.
resultsOur approach achieved 100% accuracy in distinguishing healthy samples from cancerous ones, outperforming existing methods that reported 97% accuracy. Notably, while prior methods have struggled to separate bronchogenic carcinoma stages effectively, our research achieved an approximate accuracy of 77% in stage classification. Furthermore, using gene enrichment methods, we identified 5, 7, and 16 diagnostic biomarker candidates for stages I, II, III, and IV, respectively.
conclusionThis study demonstrates that integrating bioinformatics, gene set enrichment, and biological pathway analysis can enable non-invasive diagnostics for bronchogenic carcinoma stages. These findings hold promise for developing alternatives to traditional, invasive staging systems, potentially improving patient outcomes and reducing healthcare costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.